Payment overview · 2025
General Payments
$858.75
36 reported records · 11 companies
Healthcare provider profile · identity verified
Terry Olean Harrison, M.D.
Allopathic & Osteopathic Physicians|General Practice · PARIS, TN · NPI 1063494193
Verified facts
What the public records show
CMS Open Payments records show Terry Olean Harrison, M.D. received $858.75 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $226.41 | 26.4% | 12 | 2025 |
| KLS-Martin L.P. | Unresolved — no canonical attribution shown | $213.28 | 24.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $161.04 | 18.8% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $69.14 | 8.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.34 | 5.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.84 | 4.3% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $32.48 | 3.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.85 | 3.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.74 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.13 | 1.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.50 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $826.27 | 34 |
| Education | $32.48 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $161.04 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $89.89 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $81.61 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $69.14 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $54.91 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.34 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.34 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.84 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $32.48 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.85 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
69 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
340 | 58 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 911 | 211 |
| Omeprazole | Omeprazole | 786 | 189 |
| Losartan Potassium | Losartan Potassium | 763 | 184 |
| Tramadol Hcl | Tramadol Hcl | 746 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 734 | 183 |
| Gabapentin | Gabapentin | 721 | 150 |
| Furosemide | Furosemide | 710 | 179 |
| Lisinopril | Lisinopril | 584 | 154 |
| Potassium Chloride | Potassium Chloride | 554 | 153 |
| Levothyroxine Sodium | Levothyroxine Sodium | 543 | 123 |
| Alprazolam | Alprazolam | 542 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 541 | 142 |
| Metformin Hcl | Metformin Hcl | 511 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 461 | 120 |
| Simvastatin | Simvastatin | 383 | 111 |
| Metoprolol Tartrate | Metoprolol Tartrate | 344 | 88 |
| Eliquis | Apixaban | 340 | 58 |
| Meloxicam | Meloxicam | 329 | 85 |
| Diclofenac Sodium | Diclofenac Sodium | 328 | 109 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 312 | 87 |
| Trazodone Hcl | Trazodone Hcl | 282 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 267 | 72 |
| Atenolol | Atenolol | 256 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 67 |
| Methylprednisolone | Methylprednisolone | 245 | 178 |
| Lorazepam | Lorazepam | 239 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 234 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 67 |
| Carvedilol | Carvedilol | 224 | 59 |
| Allopurinol | Allopurinol | 214 | 53 |
| Glipizide | Glipizide | 210 | 58 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 209 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 53 |
| Sertraline Hcl | Sertraline Hcl | 198 | 56 |
| Lovastatin | Lovastatin | 187 | 44 |
| Azithromycin | Azithromycin | 184 | 131 |
| Duloxetine Hcl | Duloxetine Hcl | 180 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 179 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 43 |
| Famotidine | Famotidine | 169 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 162 | 42 |
| Pregabalin | Pregabalin | 159 | 26 |
| Alendronate Sodium | Alendronate Sodium | 155 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 155 | 38 |
| Buspirone Hcl | Buspirone Hcl | 148 | 37 |
| Glimepiride | Glimepiride | 148 | 34 |
| Montelukast Sodium | Montelukast Sodium | 145 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 142 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 141 | 33 |
| Temazepam | Temazepam | 140 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 131 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 127 | 28 |
| Torsemide | Torsemide | 123 | 34 |
| Clonazepam | Clonazepam | 121 | 18 |
| Meclizine Hcl | Meclizine Hcl | 117 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 113 | 86 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 113 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 112 | 75 |
| Ibuprofen | Ibuprofen | 108 | 28 |
| Testosterone Cypionate | Testosterone Cypionate | 106 | 13 |
| Warfarin Sodium | Warfarin Sodium | 106 | 20 |
| Clonidine Hcl | Clonidine Hcl | 104 | 34 |
| Prednisone | Prednisone | 99 | 41 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 99 | 41 |
| Diazepam | Diazepam | 97 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 96 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 28 |
| Donepezil Hcl | Donepezil Hcl | 93 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 93 | 23 |
| Ozempic | Semaglutide | 92 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 91 | 17 |
| Telmisartan | Telmisartan | 89 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 87 | 40 |
| Spironolactone | Spironolactone | 84 | 28 |
| Clindamycin Hcl | Clindamycin Hcl | 80 | 50 |
| Irbesartan | Irbesartan | 78 | 19 |
| Valsartan | Valsartan | 77 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 15 |
| Metformin Hcl Er | Metformin Hcl | 73 | 19 |
| Promethazine Hcl | Promethazine Hcl | 73 | 19 |
| Sucralfate | Sucralfate | 73 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 18 |
| Nitroglycerin | Nitroglycerin | 70 | 36 |
| Dicyclomine Hcl | Dicyclomine Hcl | 69 | 18 |
| Linzess | Linaclotide | 69 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 66 | 30 |
| Ezetimibe | Ezetimibe | 66 | 21 |
| Celecoxib | Celecoxib | 62 | 22 |
| Nystatin | Nystatin | 61 | 26 |
| Baclofen | Baclofen | 59 | 13 |
| Cephalexin | Cephalexin | 59 | 22 |
| Fenofibrate | Fenofibrate | 58 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 33 |
| Gemfibrozil | Gemfibrozil | 54 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 14 |
| Levetiracetam | Levetiracetam | 50 | suppressed |
| Acyclovir | Acyclovir | 48 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 48 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 11 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Naproxen | Naproxen | 46 | 11 |
| Nifedipine Er | Nifedipine | 46 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | 14 |
| Lamotrigine | Lamotrigine | 45 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | suppressed |
| Klor-Con M20 | Potassium Chloride | 43 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 43 | 14 |
| Estradiol | Estradiol | 42 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | 12 |
| Valacyclovir | Valacyclovir Hcl | 42 | 12 |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Novolog Flexpen | Insulin Aspart | 41 | suppressed |
| Amoxicillin | Amoxicillin | 40 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 17 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Primidone | Primidone | 37 | 12 |
| Topiramate | Topiramate | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Klor-Con M10 | Potassium Chloride | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 22 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 29 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Cilostazol | Cilostazol | 27 | suppressed |
| Colchicine | Colchicine | 27 | 14 |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Premarin | Estrogens, Conjugated | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 12 |
| Ramipril | Ramipril | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 22 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Minoxidil | Minoxidil | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Cartia Xt | Diltiazem Hcl | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Indapamide | Indapamide | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Zonisamide | Zonisamide | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Lunesta | Eszopiclone | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $858.75 · 36 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Arikayce, BREZTRI, CAPLYTA, FARXIGA, JARDIANCE, NURTEC ODT, Ozempic, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error